London's Health-Tech Innovator Lands £3.7 Million Investment

uMed Secures £3.7 Million to Super‑Charge Clinical Research

Think of a world where hospitals, GPs and specialists can launch big‑scale studies without drowning in paperwork. uMed says that world is here, and they’ve just pocketed £3.7 million in venture capital to make it happen.

Who’s Backing Them?

AlbionVC
Delin Ventures
Playfair Capital
Silicon Valley’s 11.2 Capital – to give uMed a stronger foothold in the US

What uMed Actually Does

Every day, doctors juggle charting, patient care and research. uMed’s platform hand‑holds them by:

Digitally targeting patients for studies
Enabling e‑consent that’s as easy as a click
Gathering structured outcomes remotely—and feeding them straight back into the patient’s record

And the company’s already working with the University of Oxford’s RAPTOR‑C19 study, a national effort to compare rapid COVID‑19 tests across community settings—from GP surgeries to home visits. Those results are guiding the UK’s widescale testing strategy.

Beyond COVID‑19

uMed’s automation doesn’t just stop at the pandemic. It lets any practice—whether a tiny GP clinic or a sprawling hospital—take part in multiple research programmes at once. The result? More research revenue. The best part? They can do this without adding extra burden to the frontline staff.

Why It Matters

Clinical trials can cost millions. Astonishingly, up to 80 % of those expenses come from manual tasks that uMed eliminates. That translates into faster, higher‑quality data for life‑science companies—without compromising patient privacy or consent.

Dr. Matt Wilson, uMed’s founder and a former NHS anaesthetist turned Royal Marine Medical Officer, says:

“Traditional research registries are a nightmare—laborious, paperwork‑heavy, and time‑consuming.
Our tech reaches back into the Electronic Health Record, pulls patients forward, and then builds research registries automatically. Clinicians can concentrate on care; patients can opt into volunteer studies from the comfort of their own homes, with full transparency over how their data is used.”

Global Footprint

1.7 million patients across 160+ UK primary care sites
Two million patients from a major US health system (roll‑out expected next year)

In a nutshell, uMed is the bridge that lets healthcare providers and researchers work hand‑in‑hand, turning clinical data into research gold—quickly, safely, and dramatically cheaper.